Type 2 Diabetes

Does microvascular disease burden predict future cardiovascular events in type 2 diabetes? Dr. Bobby Lazzara discusses this question.

Although intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become the therapeutic mainstay for diabetic macular edema and neovascular age-related macular degeneration, it poses a risk of noninfectious uveitis or infectious endopthalmitis.

A retrospective analysis of diabetes and prediabetes diagnoses found that screening guidelines from the United States Preventative Service Task Force (USPSTF) would have detected less than half of all cases that were discovered.

Diabetes may have its roots in endocrinology but in recent years it has proven to be an issue affecting specialities across medicine. Because of that it takes more than one specialist to provide the best possible care for patients with the condition.

At the recent American Diabetes Association annual meeting Lilly Diabetes had more than 60 disclosures discussing their latest work in the field. Of all that work the Mosaic study was arguably the biggest news to come out of New Orleans.

Our July list of news and research includes LEADER and EMPA-REG trial results, kidney and cardiovascular health, and cognitive issues.

In this Medical News Minute, Dr. Bobby Lazzara discusses the findings of the 2nd Diabetes Surgery Summit regarding bariatric surgery and diabetes.

This slideshow highlights several studies regarding the effects of SGLT2 inhibitors, which were presented at the 2016 ADA Scientific Sessions.

Researchers investigated changes in biomarker levels of obese patients with type 2 diabetes taking dapagliflozin.

Analysis of 2 large health worker cohorts suggests that people can reduce their risk of developing diabetes by preparing more of their meals at home.

How can we facilitate fewer hypoglycemic episodes and better equip patients to handle those that do occur?

What role, if any, does vitamin D play in the development of diabetes or diabetic complications?

While public health organizations used to recommend low-fat/low-calories diets for people seeking to lose weight, in recent years, low-carbohydrate diets have been shown to be effective.

As healthcare professionals are well aware, more than 9% of Americans have diabetes, and most have type 2 diabetes.

Could a patient’s own stem cells be used to create insulin-secreting cells, even if that patient has type 1 diabetes?

Placement of the Ozurdex sustained-release dexamethasone implant in 29 patients with persistent diabetic macular edema resulted in a significant improvement in visual acuity and a significant decrease in central macular thickness 6 months after implantation.

A simple new blood test can accurately predict Type 2 diabetes risk better than traditional glucose measures among women with gestational diabetes.

When it comes to diabetes nutrition, patients do best when they get specific instructions on what and how to eat.

Low birth weight caused by genetic factors appears to increase the risk of developing type 2 diabetes later in life.

Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.

Glucagon-like peptide 1 (GLP-1) agonists are highly potent second-line agents for type 2 diabetes, protecting and improving beta-cell function and have a favorable adverse effect profile.

On a global scale each year, half the number type 2 diabetics are undiagnosed with the average age of onset steadily falling.

Type 2 diabetes increases the risk of both nocturnal intermittent hypoxia and sleep fragmentation, and type 2 diabetics are up to 20 times more likely to suffer from sleep apnea-hypopnea syndrome.

The Food and Drug Administration (FDA) recently approved insulin glargine U-300 (Toujeo®), and insulin lispro U-200 (Humalog® U-200).

Investigators examined cardiovascular risk with the new basal insulin peglispro compared to insulin glargine or NPH in diabetic patients.

The introduction of anti-VEGF drugs should have prevented vision loss and even blindness in many diabetics. But physicians are not using these drugs as frequently as researchers recommend, a study finds.

In patients diagnosed with psoriasis, disease severity has been strongly associated with developing a higher risk of comorbidities affecting the kidney, liver, and pancreas.

A 20-year study examined the long-term effect of cardiorespiratory fitness on risk of developing prediabetes or diabetes.

Aging may be beneficial to diabetes patients. Recent findings suggest a cellular aging process may, unexpectedly, enhance insulin secretion.

A long-term outcomes trial finds that, compared to placebo, use of the diabetes medication liraglutide (Victoza) is associated with lower rates of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death.